Global Radiation Pneumonitis Treatment Market By Risk of Development (Patient-Related Factors, Pre-Existing Lung Conditions, Smoking Associated Hypoxia, Treatment-Related Factors, Chemotherapy, Immunotherapy, Radiation Therapy, Surgery), By Technologies (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery), By End-Users (Hospitals, Research Centers & Laboratories, Research Institutions), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Pneumonitis caused by radiation is a type of lung injury. While bacteria or viruses cause pneumonia, an irritant causes pneumonitis, which is similar to an allergy. After receiving radiation treatments to the lungs or chest area, some individuals develop radiation pneumonitis. Pneumonitis affects 5-15% of individuals who receive radiation treatment for lung cancer. It usually appears around 4-12 weeks following radiation treatment, however, it can appear as soon as one week after treatment.

In other circumstances, it grows over several months at a gradual pace. A long course of corticosteroids, such as prednisone, is the most usual treatment for severe pneumonitis. These are potent anti-inflammatory drugs that work by suppressing individual immune systems to minimize inflammation of the lungs. During the process of treatment, a patient may require oxygen therapy to assist with breathing, depending on the symptoms of a given patient.

Detailed Segmentation –

The global radiation pneumonitis treatment market is segmented on the basis of – Risk of Development, Technologies, End-User, and Region. Represented below is a detailed segmental description:

Based on Risk of Development:

• Patient-Related Factors
• Pre-Existing Lung Conditions
• Smoking Associated Hypoxia
• Treatment-Related Factors
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery

Based on Technologies:

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery

Based on End-User:

• Hospitals
• Research Centers & Laboratories
• Research Institutions

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Radiation Pneumonitis Treatment Market:

The risk of developing radiation pneumonitis as a result of patient-related and treatment-related factors is expected to propel the demand for radiation pneumonitis treatment. Radiation pneumonitis is more likely to develop as a result of patient-related characteristics such as age, gender, smoking status, performance status, and underlying pulmonary disorders.

The development of novel approaches for the prevention and treatment of radiation pneumonitis, as well as advances in the knowledge of molecular mechanisms underlying tissue damage, have resulted in a surge in the demand for radiation pneumonitis treatment.

Competitive Landscape-

Key players in this market are –

• Provision Healthcare LLC
• Hitachi Ltd.
• Elekta AB
• C. R. Bard Inc.
• Optivus Proton Therapy Inc.
• Mevion Medical Systems Inc.
• Panacea Medical Technologies Pvt. Ltd.
• Isoray Medical Inc.
• Varian Medical Systems Inc.
• others

These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edge.

For the Radiation Pneumonitis Treatment Market research study, the following years have been considered to estimate the market size: